Applicant, as named in the Orange Book
Glaxosmithkline Llc
GSK plc · NYSE: GSK
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Lamictal Xr on 7 Jan 2029. 1 products with live protection, 4 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Lamictal Xr NDA 022115 · 6 strengths lamotrigine | 7 Jan 2029 patent |
Recent events
- Lamictal Odt · Generic approved · ANDA 217100, TorrentApproved 8 Jan 2026Detected 25 Oct 2026
- Requip Xl · Generic approved · ANDA 217862, Elite Labs IncApproved 10 Nov 2025Detected 25 Oct 2026
- Lamictal Odt · Generic approved · ANDA 219677, TaroApproved 7 Oct 2025Detected 25 Oct 2026
- Lamictal Odt · Generic approved · ANDA 217278, AlembicApproved 25 Feb 2026Detected 25 Oct 2026
Products without listed protection (4)
| Drug | Earliest generic entry |
|---|---|
| Lamictal NDA 020241 · 4 strengths lamotrigine | open now no listed protection |
| Lamictal Cd NDA 020764 · 3 strengths lamotrigine | open now no listed protection |
| Lamictal Odt NDA 022251 · 4 strengths lamotrigine | open now no listed protection |
| Mepron NDA 020500 atovaquone | open now no listed protection |